Price (delayed)
$71.38
Market cap
$7.57B
P/E Ratio
56.2
Dividend/share
N/A
EPS
$1.27
Enterprise value
$7.49B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
There are no recent dividends present for CORT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.